EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., Calagua, C., Ye, H., Pantelidou, C., Galbo, P., Panja, S., Mitrofanova, A., Wilkinson, S., Whitlock, N. C., Trostel, S. Y., Hamid, A. A., Kibel, A. S., Barbie, D. A., Choudhury, A. D., Pomerantz, M. M., Sweeney, C. J., Long, H. W., Einstein, D. J., Shapiro, G. I., Dougan, S. K., Sowalsky, A. G., He, H. H., Freedman, M. L., Balk, S. P., Loda, M., Labbé, D. P., Olson, B. M., & Ellis, L. (2021). EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer, 2(4), 444-456.